Compliance Team
Angels Den

Dear User,

You may have heard about the new General Data Protection Regulation (“GDPR”), that comes into effect May 25, 2018.

We would like to ensure you that your personal data is safe with us. Please read the details regarding the processing of your personal data and if you agree with the processing as described below, please click the ‘I agree’ button.

Please be informed that you can withdraw this consent at any time.

1) What data are we talking about?

We are disclosing details regarding the processing of personal data that is collected within our calls and in connection with your use of Angels Den’s platform, Websites and other functionalities of Angels Den, including those saved in cookies files.

2) Who will be the controller of your data?

Angels Den Funding Limited (hereinafter referred to as AD) will be the controller of your data (Angels Den means all entities from the Angels Den capital group, which includes Angels Den Funding Limited with its registered office in London and all entities related to it and dependent on it) and only our Trusted Partners.

3) Why do we want to process your data?

We process this data for the purposes described in our Privacy Policy, including:
- compliance with any legal requirements and obligations,
- ensuring that content from our Website is presented in the most effective manner for you,
- marketing purposes,
- providing you with our services (including the completion and support of immediate activity required to provide you with information and deliver products and/or services that you request and to deliver any contracts entered into with you), or
- as otherwise explained in this privacy policy or by any communication by us.
Where you have explicitly consented to be contacted for such purposes, we use your personal data to provide information on our new and existing products and services.

4) To whom can we transfer data?

In accordance with applicable law, we may transfer your data to entities processing it at our request, e.g. marketing agencies, subcontractors of our services and entities authorized to obtain data under applicable law, e.g. courts or law enforcement agencies - of course only if they submit a request based on an applicable legal basis. Furthermore, we will transfer your data to Trusted Partners outside the European Union – to the USA – under the EU-U.S. Privacy Shield Framework.

5) What are your rights to your data?

You have the right to request access to, correct, delete your personal data. You can also withdraw consent to processing of personal data, raise objections and use other rights granted under GDPR (i.e. right to data portability).

6) Use of cookies

We use cookies to give you the best experience on our Website. This means that we have placed cookies on your device. If you continue without changing your cookie settings, we assume that you consent to our use of cookies on this device. You can change your cookie settings at any time but if you do, you may lose some functionality on our Website. More information can be found in our Privacy Policy.

In connection with the above, I agree to the processing of my personal data by Angels Den and its Trusted Partners. I confirm that I understand that my personal data is being collected as part of my phone calls, use of AD’s online platform, Websites, and other functionalities of AD, including the data saved in cookie files. I also consent to profiling in order to allow Angels Den and its Trusted Partners the provision of better services (including for analytical purposes). Your data will only be processed on a valid lawful basis in accordance with applicable data protection laws. The processing of your personal data for marketing purposes (including statistical analysis) by AD is based on the firm's legitimate interest. The processing for marketing purposes by our Trusted Partners is only possible if we receive your freely given consent. We will also process your personal data to fulfil our contractual obligations to you as contained in AD’s Terms and Conditions of the use of our Website and services. Therefore, this data will be processed on another lawful basis – ‘contract’. We will also process your data to comply with our legal obligations for our Service (such as anti money laundering and know your customer requirements), which is also a valid lawful basis in accordance with applicable data protection laws.

Expressing this consent is voluntary and you can withdraw at any time.

If you have any doubts or questions about the use of your personal data, please do not hesitate to contact me via email. I’m happy to assist.

Compliance Team
Angels Den
cl@angelsden.com

  • £ 150,000 FUNDED SO FAR (100 %)
  • £ 2,000,000 MAXIMUM TARGET
  • 20.00% EQUITY
  • 0 DAYS
  • SIGN IN TO SEE MORE
100%

NOVAI LIMITED - Investment Opportunity

Novai is an innovative UK biotechnology company, developing and commercialising transformational and disruptive technology in the ophthalmology area developed by Professor M Francesca Cordeiro at UCL and Imperial College, through Wellcome Trust Innovation funding. Professor Cordeiro developed DARC (Detection of Apoptosing Retinal Cells) over the last decade with a mission to improve patients’ lives through early diagnosis of neurodegenerative diseases, with the ultimate aim of preventing functional loss. Our initial focus is on ophthalmic disorders with high unmet need such as glaucoma and AMD (Age-related Macular Degeneration).

LIVE PITCHING

Novai pitching at an Angels Den online event

You have to log in or register to see this information.
INTERVIEW WITH ENTREPRENEUR

Interview with Dr Francesca Cordeira and Aman Kahn from Novai

INTERVIEW WITH LEAD INVESTOR

Interview with Novai's executive chairman and investor Dr Berwyn Clarke

THE IDEA
Products & Services

Our technology consists of a patented biological marker combined with a bespoke and patented Artificial Intelligence (AI) aided algorithm, allowing, for the first time in vivo, identification of cellular level disease activity in the retina. DARC consists of a fluorescent labeled Annexin protein, which binds to stressed and apoptotic cells in the retina.

The Company will sell access to its technology via a SAAS model, shipping product to customer sites and providing analysis using its AI algorithm via a cloud-based system. The Company will train the customer or the customer's Contract Research Organisation (CRO). The Company collates the data and provides a report to the customer.

Problem Solved

Clinical drug development is costly, time consuming, and carries a high degree of risk. Current clinical endpoints detect late changes, only after significant damage has been done to retinal cells. There is a lack of early disease biomarkers to objectively detect and measure cell health and response to treatment.

The DARC protein is administered via intravenous injection. Retinal images are taken (using standard imaging equipment), with individual apoptotic cells visible as white spots on the retina. The AI algorithm identifies the number and distribution of DARC spots, producing an objective 'DARC Count' report. Successful treatments will show a reduction in DARC count within weeks.

Revenue Model

There are two revenue channels: Pre-clinical (lab) trials, and clinical (human) trials.

Pre-clinical trials will generate £150K - £250K per compound tested (companies will provide compounds for testing with DARC, to determine their efficacy and suitability to advance to clinical trials).

For clinical trials, DARC is sold on a per-injection basis. Clinical trial revenues will range between £800K-£10M, depending on the number of patients tested and the duration of the trial. Patients are injected during triage (to identify fast progressing patients enabling enrichment of the trial cohort), then again at several time points during the trial.

Exit Strategy
You have to log in or register to see this information.
Minimum Target £ 150,000 Maximum Target £ 2,000,000 Minimum investment amount £ 10,000 Maximum investment amount £ 2,000,000
Share On Website Visit site Location READING
Gallery

The Idea

Products & Services

Our technology consists of a patented biological marker combined with a bespoke and patented Artificial Intelligence (AI) aided algorithm, allowing, for the first time in vivo, identification of cellular level disease activity in the retina. DARC consists of a fluorescent labeled Annexin protein, which binds to stressed and apoptotic cells in the retina.

The Company will sell access to its technology via a SAAS model, shipping product to customer sites and providing analysis using its AI algorithm via a cloud-based system. The Company will train the customer or the customer's Contract Research Organisation (CRO). The Company collates the data and provides a report to the customer.

Problem Solved

Clinical drug development is costly, time consuming, and carries a high degree of risk. Current clinical endpoints detect late changes, only after significant damage has been done to retinal cells. There is a lack of early disease biomarkers to objectively detect and measure cell health and response to treatment.

The DARC protein is administered via intravenous injection. Retinal images are taken (using standard imaging equipment), with individual apoptotic cells visible as white spots on the retina. The AI algorithm identifies the number and distribution of DARC spots, producing an objective 'DARC Count' report. Successful treatments will show a reduction in DARC count within weeks.

Revenue Model

There are two revenue channels: Pre-clinical (lab) trials, and clinical (human) trials.

Pre-clinical trials will generate £150K - £250K per compound tested (companies will provide compounds for testing with DARC, to determine their efficacy and suitability to advance to clinical trials).

For clinical trials, DARC is sold on a per-injection basis. Clinical trial revenues will range between £800K-£10M, depending on the number of patients tested and the duration of the trial. Patients are injected during triage (to identify fast progressing patients enabling enrichment of the trial cohort), then again at several time points during the trial.

Exit Strategy
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
  • £ 150,000 FUNDED SO FAR (100 %)
  • £ 2,000,000 MAXIMUM TARGET
  • 20.00% EQUITY
  • 0 DAYS
  • SIGN IN TO SEE MORE
100%